Publications

Novel CD45-targeted TCR-T cell therapies designed to eliminate residual disease and prevent relapse following hematopoietic cell transplantation

TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning: Updated Results from the Phase 1 (ALLOHA) Trial

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial.

Identification of Novel HLA Class II–Restricted Autoantigens in CD4⁺ T Cell– Driven Autoimmune Diseases Using TargetScan.